Therefore, patients who may benefit from future immunotherapies may not be the ones with activated TRM who already have generated a good immune prognosis but those patients who have shown the ability to recruit CD8 T-cells but have so far failed to convert this to a survival advantage: the left-sided colon cancer patients with high CD8 T-cells and low recently activated TRM. This evidence concerns the gene CD8A and malignant colon neoplasm.